{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:35:33Z","timestamp":1790386533500,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,4]]},"DOI":"10.7759\/cureus.16881","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T15:54:49Z","timestamp":1628092489000},"source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis"],"prefix":"10.7759","author":[{"given":"Jessica","family":"Hidalgo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P","family":"Fabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eissa-Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina D","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Tirupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5010017","article-title":"Innovative partnerships for the elimination of human African trypanosomiasis and the development of fexinidazole","volume":"5","author":"Neau P","year":"2020","unstructured":"Neau P, H\u00e4nel H, Lameyre V, Strub-Wourgaft N, Kuykens L. Innovative partnerships for the elimination of human African trypanosomiasis and the development of fexinidazole. Trop Med Infect Dis. 2020, 5:17. 10.3390\/tropicalmed5010017","journal-title":"Trop Med Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto G","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, et al.. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009, 374:56-64. 10.1016\/S0140-6736(09)61117-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04555-8","article-title":"An atlas of tsetse and animal African trypanosomiasis in Zimbabwe","volume":"14","author":"Shereni W","year":"2021","unstructured":"Shereni W, Neves L, Argil\u00e9s R, Nyakupinda L, Cecchi G. An atlas of tsetse and animal African trypanosomiasis in Zimbabwe. Parasit Vectors. 2021, 14:50. 10.1186\/s13071-020-04555-8","journal-title":"Parasit Vectors"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-018-2634-x","article-title":"A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"Kansiime F","year":"2018","unstructured":"Kansiime F, Adibaku S, Wamboga C, et al.. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasit Vectors. 2018, 11:105. 10.1186\/s13071-018-2634-x","journal-title":"Parasit Vectors"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00321-3","article-title":"Treatment of human African trypanosomiasis - present situation and needs for research and development","volume":"2","author":"Legros D","year":"2002","unstructured":"Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, B\u00fcscher P. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect Dis. 2002, 2:437-40. 10.1016\/S1473-3099(02)00321-3","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy PG","year":"2013","unstructured":"Kennedy PG. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol. 2013, 12:186-94. 10.1016\/S1474-4422(12)70296-X","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5010005","article-title":"Clinical study on the melarsoprol-related encephalopathic syndrome: risk factors and HLA association","volume":"5","author":"Seixas J","year":"2020","unstructured":"Seixas J, Atouguia J, Josenando T, Vatunga G, Bilenge CM, Lutumba P, Burri C. Clinical study on the melarsoprol-related encephalopathic syndrome: risk factors and HLA association. Trop Med Infect Dis. 2020, 5:5. 10.3390\/tropicalmed5010005","journal-title":"Trop Med Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2018.04.002","article-title":"Melarsoprol resistance in African trypanosomiasis","volume":"34","author":"Fairlamb AH","year":"2018","unstructured":"Fairlamb AH, Horn D. Melarsoprol resistance in African trypanosomiasis. Trends Parasitol. 2018, 34:481-92. 10.1016\/j.pt.2018.04.002","journal-title":"Trends Parasitol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1086\/522982","article-title":"Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"Priotto G","year":"2007","unstructured":"Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007, 45:1435-42. 10.1086\/522982","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001920","article-title":"In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness","volume":"6","author":"Schmid C","year":"2012","unstructured":"Schmid C, Kuemmerle A, Blum J, et al.. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis. 2012, 6:10.1371\/journal.pntd.0001920","journal-title":"PLoS Negl Trop Dis"},{"key":"ref13","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"Franco JR","year":"2012","unstructured":"Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Samo M, Jannin JG. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med. 2012, 3:93-101.","journal-title":"Res Rep Trop Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: m\u00e9decins sans fronti\u00e8res experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol E","year":"2013","unstructured":"Alirol E, Schrumpf D, Heradi JA, Riedel A, de Patoul C, Quere M, Chappuis F. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: m\u00e9decins sans fronti\u00e8res experience in the Democratic Republic of the Congo. Clin Infect Dis. 2013, 56:195-203. 10.1093\/cid\/cis886","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu VK","year":"2018","unstructured":"Mesu VK, Kalonji WM, Bardonneau C, et al.. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018, 391:144-54. 10.1016\/S0140-6736(17)32758-7","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00208-4","article-title":"Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study","volume":"9","author":"Mesu VK","year":"2021","unstructured":"Mesu VK, Kalonji WM, Bardonneau C, et al.. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021, 9:999-1008. 10.1016\/S2214-109X(21)00208-4","journal-title":"Lancet Glob Health"},{"key":"ref17","article-title":"Chemotherapy for second-stage human African trypanosomiasis","volume":"2013","author":"Lutje V","year":"2013","unstructured":"Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database Syst Rev. 2013, 2013:CD006201.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser M","year":"2011","unstructured":"Kaiser M, Bray MA, Cal M, Trunz BB, Torreele E, Brun R. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011, 55:5602-8. 10.1128\/AAC.00246-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-52727-9.00023-6","article-title":"Nanoarchitectures for neglected tropical protozoal diseases: challenges and state of the art","author":"Pund S","year":"2017","unstructured":"Pund S, Joshi A. Nanoarchitectures for neglected tropical protozoal diseases: challenges and state of the art. Nano- and Microscale Drug Delivery Systems: Design and Fabrication. Elsevier Inc., Philadelphia, PA; 2017. 439-80. 10.1016\/B978-0-323-52727-9.00023-6"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000064","article-title":"Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series","volume":"1","author":"Checchi F","year":"2007","unstructured":"Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007, 1:10.1371\/journal.pntd.0000064","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62879-efficacy-and-toxicity-of-fexinidazole-and-nifurtimox-plus-eflornithine-in-the-treatment-of-african-trypanosomiasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:58Z","timestamp":1707507178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62879-efficacy-and-toxicity-of-fexinidazole-and-nifurtimox-plus-eflornithine-in-the-treatment-of-african-trypanosomiasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.16881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}